You are here: Industry Insights > NMPA

News List

Everest Medicines Announces Acceptance of New Drug Application by China NMPA for Xerava(TM) for the Treatment of Complicated Intra-abdominal Infections prnasia
March 22, 2021
Everest Medicines, a biopharmaceutical company focused on developing and commercializing transformative pharmaceutical products that address critical unmet medical needs for patients in Greater China and other parts of Asia, announced today that the ...
NMPA Accepts Application for Clinical Trial of Bifunctional Fusion Protein contractpharma
March 10, 2021
JS201, developed by Junshi Biosciences, can simultaneously target PD-1 and TGF-β.
Tigermed Supported and Delivered Clinical Study of CanSino COVID-19 Vaccine as Clinical Contract Research Organization prnasia
February 26, 2021
China National Medical Products Administration (NMPA) announced on February 25 to grant conditional marketing authorization of Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector).
Antengene Announces NDA for ATG-010 (Selinexor) Granted Priority Review by China's NMPA prnasia
February 24, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, today announced that China's ...
The BCMA CAR-T Co-developed by Innovent and IASO Was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma prnasia
February 23, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and IASO Biotherapeutics (IASO Bio) ...
China approves AstraZeneca’s Forxiga for heart failure pharmaceutical-technology
February 07, 2021
China’s National Medical Products Administration (NMPA) has approved AstraZeneca’s Forxiga (dapagliflozin) for heart failure with reduced ejection fraction (HFrEF) in adults with and without type-2 diabetes.
Innovent and Lilly Jointly Announce the Approval of TYVYT® (sintilimab injection) by China NMPA in Combination with Pemetrexed and Platinum Chemotherapy as First-Line Therapy for Nonsquamous Non-Small prnasia
February 03, 2021
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, and Eli Lilly and Company, today ...
Kintor's GT20029 IND for PROTAC AR Degrader Was Accepted by NMPA prnasia
February 02, 2021
Kintor Pharmaceutical Limited is pleased to announce that the investigational new drug application of GT20029 for androgenetic alopecia and acne vulgaris indications has been accepted by the National Medical Products Administration of China.
Antengene Announces the Acceptance of ATG-010 (Selinexor) NDA by the NMPA for the Treatment of rrMM prnasia
January 28, 2021
Antengene Corporation Limited, a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in class therapeutics in hematology and oncology, announced that the ...
CPhI & P-MEC China gives a glimpse of the success returning pharma events will deliver in 2021 PharmaSources.com
January 20, 2021
The fully launched MAH and priority review pathways from the NMPA (National Medical Products Administration) is stimulating new demand in China for 2021.

Previous page 1 2 3 4 5 6 7 8 9 10 11 12 13 Next page